References

1. Dixon GW, Schlesselman JJ, Ory HW et al. Ethinyl estradiol and conjugated estrogens as postcoital contraceptives. JAMA 1980;244(12):1336-39.
2. Dominik R, Trussell J, Dorflinger L. Emergency contraception use and the evaluation of barrier contraceptives: new challenges for study design, implementation and analysis. Contraception (accepted for publication).
3. Glasier A, Baird D. The effects of self-administering emergency contraception. N Engl J Med 1998;339(1):1-4.
4. Hatcher RA, Trussell J, Stewart F et al. Contraceptive Technology. 17th ed. New York: Ardent Media, 1998.
5. Johnson NL, Kotz S, Kemp AW. Univariate Discrete Distributions. 2nd ed. New York: Wiley, 1993.
6. Raymond EG, Dominik R, Spermicide Trial Group. Contraceptive effectiveness of two spermicides: a randomized trial. Obstet Gynecol (accepted for publication).
7. Schwartz D, Macdonald PDM, Heuchel V. Fecundability, coital frequency and the viability of ova. Popul Stud 1980;34(2):397-400.
8. Steiner MJ, Hertz-Picciotto I, Schultz KF et al. Measuring true contraceptive efficacy: a randomized approach -- condom versus spermicide versus no method. Contraception (accepted for publication).
9. Trussell J, Rodriguez G, Ellerston C. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception 1998;57(6):363-69.
10. WHO Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998;352(9126):428-33.
11. Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation: effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl J Med 1995;333(23):1517-21.

Acknowledgments

This meeting resulted from the collaborative planning of the committee members shown below. We wish to acknowledge the work of others who made this meeting possible. The morning presentations helped establish a common base of knowledge for the day's discussions. In addition to presentations by several members of the planning team, we appreciate presentations prepared by: Colin Pollard of the U.S. Food and Drug Administration, Felicia Stewart of the Henry J. Kaiser Family Foundation, Terri Walsh of the California Family Health Council, Tim Farley of the World Health Organization, and Markus Steiner of Family Health International (FHI). In addition, we appreciate the contributions made by all of the participants during the afternoon discussions, moderated by FHI President Willard Cates, Jr. This was truly a participatory meeting, and without the contributions made by all of the participants, we would not have achieved our purpose. Finally, we thank the U.S. Agency for International Development for supporting the cost of the meeting.

Planning Committee:

Rosalie Dominik, MPH
Director of Biostatistics
Family Health International

Laneta Dorflinger, PhD
Vice President of Research and Development
Family Health International

Christine Mauck, MD
Medical Director
Contraceptive Research and Development Program

Rebecca Pinario
Administrative Assistant
Family Health International

Elizabeth Raymond, MD, MPH
Associate Medical Director
Family Health International

Jocelyn Thornton, BS
Regulatory Affairs and Quality Assurance Associate
Family Health International

James Trussell, PhD
Professor of Economics and Public Affairs
Princeton University

** This publication is supported in part by the U.S. Agency for International Development. The contents do not necessarily reflect FHI or USAID policy.

return to table of contents